Director Robert Demichiei buys 11,260 shares of ARDT at $8.73, raising holdings to 35,564 shares; stock down -44.2% from 52-week high.
Director Robert Demichiei purchased 11,260 shares at $8.73 on 2026-06-05, increasing his shareholding by 46.3% from 24,304 to 35,564 shares for a total investment of $98,299.80. The purchase occurs with the stock trading at $8.64, down -44.2% from its 52-week high of $15.48 and down -14.5% over the past 30 days. Ardent Health trades at a P/E of 9.19 with positive fundamentals including $1.6B in quarterly revenue, $39.8M in net income, and 6.0% annual revenue growth, suggesting the depressed price may reflect market sentiment rather than deteriorating business performance. The substantial increase in Demichiei's ownership stake warrants tracking to establish whether this represents a broader pattern of insider accumulation at current valuations.
CFO Alfred Lumsdaine buys 10,000 shares of ARDT at $8.81 as stock down -44.2% from 52-week high
Alfred Lumsdaine, Chief Financial Officer, purchased 10,000 shares at $8.81 on 2026-06-05, expanding his holdings to 329,183 shares (a +3.1% increase). The purchase occurs against a backdrop of significant recent price weakness: the stock trades 44.2% below its 52-week high of $15.48 and has declined 14.5% over the past 30 days. The company's fundamentals remain solid with annual revenue growth of +6.0%, a P/E of 9.19, and quarterly revenue of $1.6B, suggesting the price decline has not been driven by fundamental deterioration. The timing of a CFO equity purchase during a period of sharp drawdown merits attention, though the transaction's ultimate significance will depend on whether this represents a standalone opportunistic entry or a broader pattern of insider accumulation.
Add ARDT to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.
